Share ownership Abbisko Cayman Limited

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 09:08:13 09/06/2026 BST			5-day change	1st Jan Change
8.700 ^HKD	-0.80%		-8.61%	-33.13%

04-29	Abbisko Completes HK$523 Million Share Offering	MT
04-23	Abbisko Therapeutics Showcases Six Research Advances Highlighting Pan-KRAS, 4th Generation EGFR, And Synthetic Lethality Approaches	CI

Share class: Abbisko Cayman Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	716,411,350	583,018,801 ( 81.38 %)	0	81.38 %

Major shareholders: Abbisko Cayman Limited

Name	Stocks	%	Valuation
Yao Chang Xu 11.2 %	81,099,968	11.2 %	101 M $
Qiming Venture Partners Ltd. 5.68 %	41,136,370	5.68 %	51 M $
LAV Management Co., Ltd. 5.648 %	40,905,790	5.648 %	51 M $
Allianz Global Investors Asia Pacific Ltd. 5.418 %	39,241,000	5.418 %	49 M $
GIC Pte Ltd. (Investment Management) 5.247 %	38,000,000	5.247 %	47 M $
Futu Trustee Ltd. 4.279 %	30,988,050	4.279 %	39 M $
Hong Ping Yu 2.432 %	17,612,962	2.432 %	22 M $
Zhui Chen 2.376 %	17,207,394	2.376 %	21 M $
Fidelity Management & Research (Hong Kong) Ltd. 1.63 %	11,802,000	1.63 %	15 M $
Value Partners Ltd. 0.6089 %	4,410,000	0.6089 %	5 M $
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	26.35%
Individuals	16.43%
Others	4.28%
Unknown	52.94%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	16.43%
China	12.41%
Hong Kong	12.09%
Singapore	5.25%
United States	0.85%
Ireland	0.04%

Based on 1000 largest holdings

Abbisko Cayman Ltd is a clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Companyâ€™s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Employees

276

Sector

Biotechnology & Medical Research

More about the company